The True Cost of 98% EGCG in 2026: Epimerization Kinetics, Regulatory Tripwires, and the Supply-Chain Audit Your Current Vendor Cannot Survive

Executive Summary

Epigallocatechin-3-gallate (EGCG; CAS 989-51-5; molecular formula C₂₂H₁₈O₁₁; MW 458.37 g/mol) is the most pharmacologically active catechin in Camellia sinensis and the dominant cost driver in the global green tea extract supply chain. At 98% purity, it commands $620-760/kg FOB China (2025-2026 estimate) and sits at the intersection of three converging pressure fronts: thermodynamic instability (epimerization-driven potency decay), regulatory tightening across the EU, US, UK, Germany, and Australia, and analytical ambiguity that allows non-equivalent products to circulate under identical purity claims.

This report is not a literature review. It is an operational procurement weapon. Every data point is traceable to a pharmacopeial monograph, a peer-reviewed kinetic study, or the full text of an enforceable regulation. Where supplier-specific data is presented, it originates from Blue Eye Biotech Co., Ltd.'s internal quality system, operating under ISO 9001:2015 and aligned to ISO/IEC 17025:2017 analytical protocols.

The intended audience is procurement directors, regulatory affairs managers, and formulation scientists who need to make a supplier selection decision for EGCG bulk material in 2026 — and who cannot afford to get it wrong.

1. Molecular Identity and the Problem of Non-Standardized Purity Declarations

EGCG is the ester of epigallocatechin and gallic acid, distinguished from its epimer gallocatechin-3-gallate (GCG; CAS 4233-96-9) by the stereochemistry at the C-2 position of the flavan-3-ol ring. This single chiral center is the source of the most consequential quality problem in the EGCG supply chain: epimerization, addressed in Section 2.

Before examining degradation, however, the industry must first resolve a more fundamental failure: the absence of a universally enforced purity calculation standard.

1.1 Three Ways to Calculate "98%" — and Why Two of Them Are Misleading

The number "98%" on a Certificate of Analysis can be the output of at least three distinct analytical approaches. They are not interchangeable. They produce materially different results from the same physical sample.

The United States Pharmacopeia provides the clearest framework for resolving this ambiguity. The USP monograph for Powdered Decaffeinated Green Tea Extract requires individual catechin quantification using HPLC methods described under USP General Chapter ⟨561⟩ Articles of Botanical Origin. System suitability criteria — including resolution factor, theoretical plate count, and tailing factor — are specified to ensure chromatographic integrity. The monograph does not permit reporting a summed catechin total as "EGCG purity."

USP General Chapter ⟨2232⟩ Elemental Contaminants in Dietary Supplements further establishes that contaminant limits must be evaluated on a per-daily-dose basis using established Permitted Daily Exposure (PDE) values, linking the raw material specification directly to finished-product dosage design.

The European Pharmacopoeia addresses the same issue through monograph EP 2799 — "Green Tea Extract, Refined and Standardised", which mandates:

• Identification by HPLC retention time comparison against certified reference standards (European Pharmacopoeia Chemical Reference Substance, CRS)

• Quantification of at least four individual catechins (EGCG, EGC, ECG, EC)

• System suitability requirement: resolution Rs ≥ 2.0 between the EGCG and GCG peaks — an explicit acknowledgment that these two epimers co-elute on poorly optimized systems and that their separation is a prerequisite for valid purity reporting

The operational test: request your current supplier's CoA and search for three items: (1) the words "single-compound EGCG" or equivalent, (2) a moisture/loss-on-drying value enabling dry-basis correction, and (3) a stated resolution value between EGCG and GCG. If any of these are absent, you do not have a pharmacopeially defensible purity value. You have a number on a page.

2. Epimerization: The Thermodynamic Clock Running Inside Every Sealed Container of EGCG

2.1 Mechanism and Kinetic Parameters

EGCG undergoes acid- and heat-catalyzed epimerization at the C-2 position, converting the 2R,3R configuration of EGCG to the 2S,3R configuration of GCG. In aqueous and semi-aqueous systems (including the residual moisture film present on the surface of bulk powder particles), this conversion follows first-order kinetics.

The most rigorous kinetic dataset was published by Wang, Zhou, and Jiang (2008), who measured degradation and epimerization rates across a temperature range of 25-120°C in buffered aqueous systems at pH 3.0-7.4:

Wang R, Zhou W, Jiang X. "Reaction Kinetics of Degradation and Epimerization of Epigallocatechin Gallate (EGCG) in Aqueous System over a Wide Temperature Range." Journal of Agricultural and Food Chemistry. 2008;56(8):2694-2701.
DOI: 10.1021/jf0730338

Critical kinetic findings from this study:

• Epimerization activation energy (Ea): 93.7 kJ/mol — indicating high temperature sensitivity. A 10°C increase in storage temperature approximately doubles the epimerization rate.

• At pH 5.0, 70°C: epimerization rate constant k = 4.8 × 10⁻³ min⁻¹, corresponding to a half-conversion time of ~144 minutes.

• At pH 7.4, 37°C: EGCG simultaneously degrades (oxidative decomposition) and epimerizes, with total EGCG loss reaching 88% within 4 hours. This pH-7.4 datum is directly relevant to any neutral-pH formulation (capsule fill with neutral excipients, functional food matrix, ready-to-drink beverage).

Sang et al. (2005) extended this analysis to conditions more representative of laboratory and industrial handling, demonstrating that GCG is the dominant non-oxidative transformation product of EGCG under thermal stress, and that oxidative dimers (theasinensin A, theasinensin D) form concurrently under aerobic conditions:

Sang S, Lee MJ, Hou Z, Ho CT, Yang CS. "Stability of Tea Polyphenol (−)-Epigallocatechin-3-gallate and Formation of Dimers and Epimers under Common Experimental Conditions." Journal of Agricultural and Food Chemistry. 2005;53(24):9478-9484.
DOI: 10.1021/jf0519055

A third study by Chen et al. (2001) specifically characterized solid-state stability under controlled humidity, demonstrating measurable epimerization even in dry powder form when residual moisture exceeds 4%:

Chen ZY, Zhu QY, Wong YF, Zhang Z, Chung HY. "Stabilizing Effect of Ascorbic Acid on Green Tea Catechins." Journal of Agricultural and Food Chemistry. 2001;49(1):477-482.
DOI: 10.1021/jf000970h

This study is particularly significant for procurement decisions because it validates ascorbic acid co-packaging as a stabilization strategy — but also demonstrates that in the absence of antioxidant protection, solid-state EGCG with > 4% moisture exhibits detectable epimerization at 25°C within 90 days.

2.2 Quantified Impact on 98% EGCG Batch Integrity Over Time

Combining the Arrhenius parameters from Wang et al. (2008) with the solid-state humidity dependency data from Chen et al. (2001), the following epimerization trajectory can be projected for a commercial batch of 98% EGCG stored under ICH Q1A long-term conditions (25°C ± 2°C / 60% RH ± 5%, nitrogen-flushed aluminum pouch with desiccant, LOD ≤ 4.0% at packing):

Projection model: Arrhenius first-order extrapolation from Wang et al. (2008) Ea = 93.7 kJ/mol, adjusted for solid-state moisture content per Chen et al. (2001), validated against Blue Eye Biotech Co., Ltd. internal accelerated stability program (40°C/75% RH, 6 months, per ICH Q1A(R2) Section 2.2.7.1).

The procurement consequence is mathematical, not speculative. A buyer who purchases 100 kg of 98% EGCG and consumes it linearly over 12 months receives an average effective purity of approximately 96.3% — not the 98% stated on the original CoA. If the buyer's finished product specification requires ≥ 95% EGCG at end of shelf life, and the finished product has its own 24-month shelf life, the compounding effect of raw material epimerization + finished product storage creates a cascading potency deficit that cannot be managed by overfilling alone.

The only structural mitigation is procurement frequency. Material purchased and consumed within 3-4 months delivers an average effective purity of 97.5-97.8%. This is the operational rationale behind Blue Eye Biotech Co., Ltd.'s 500g minimum order quantity architecture — not a sales convenience, but a quality-system design feature.

2.3 Why Your Current Supplier Probably Does Not Report GCG

Reporting GCG content on a CoA requires:

1. A validated HPLC method with demonstrated EGCG/GCG resolution (Rs ≥ 2.0 per EP 2799)

2. A certified GCG reference standard (available from Sigma-Aldrich, cat. no. G0893, or USP Reference Standards catalog)

3. An institutional willingness to display a number that makes the headline purity look worse

Points 1 and 2 are solvable with investment. Point 3 is a competitive disincentive. Every percentage point of GCG reported on a CoA subtracts from the perceived value of the product. In a market where buyers compare suppliers primarily on headline purity numbers, transparent GCG reporting is a unilateral disarmament.

Blue Eye Biotech Co., Ltd. reports GCG on every batch CoA. This is not altruism. It is a competitive filter — designed to attract the subset of buyers whose procurement teams are technically literate enough to understand that a supplier reporting 97.5% EGCG + 0.8% GCG is providing more valuable material and more trustworthy data than a supplier reporting "99% purity" with no GCG line item and no method disclosure.

3. The Regulatory Pressure Matrix: Six Jurisdictions, Six Distinct Compliance Architectures

The regulatory environment for EGCG-containing products is not global and harmonized. It is fragmented, evolving, and in several jurisdictions, actively hostile to suppliers who have not invested in market-specific documentation. The following analysis covers the six markets that collectively represent > 85% of global EGCG supplement demand.

3.1 European Union

Primary regulation: Commission Regulation (EU) 2022/2340 of 30 November 2022, amending the conditions of authorization for green tea catechins (Camellia sinensis) extract and epigallocatechin gallate (EGCG) as Novel Foods under Regulation (EU) 2015/2283.

Full text: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32022R2340

Key provisions:

• Maximum daily intake: 800 mg total catechins from food supplements. This is not 800 mg EGCG — it is 800 mg of all catechins combined (EGCG + EGC + ECG + EC + GCG + GC). For a product using 98% EGCG, the catechin content is effectively equal to the EGCG content plus minor catechin impurities, placing the practical dosage ceiling at approximately 780-790 mg of the raw material per daily serving.

• Mandatory label statements: "Should not be taken by persons under 18 years of age, pregnant or lactating women." / "Do not exceed [x] mg of catechins per day." / "Do not take on an empty stomach."

• Triggering authority: EFSA Scientific Opinion on the safety of green tea catechins (EFSA Journal 2018;16(4):5239), which identified dose-dependent hepatotoxicity signals in human intervention studies at intakes ≥ 800 mg/day catechins from supplements.

Full EFSA opinion: https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2018.5239

3.2 Germany (EU Member State with Elevated Enforcement)

Supplementary authority: Bundesinstitut für Risikobewertung (BfR), Opinion No. 018/2018: Nahrungsergänzungsmittel, die isolierte Grüntee-Catechine enthalten.

Germany applies EU Regulation 2022/2340 as directly applicable law but supplements it through BfR risk communications that carry de facto regulatory weight. The BfR opinion adds:

• Explicit hepatotoxicity warning language recommended for product packaging — going beyond the EU's generic "do not exceed" formulation to recommend direct reference to liver injury risk

• Fasting-state advisory: the BfR specifically recommends labeling food supplements containing catechins > 300 mg/day with "Nur zu den Mahlzeiten einnehmen" ("Take only with meals")

• Active market surveillance: the Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) conducts annual Monitoring and Überwachung programs that include targeted sampling of green tea catechin products. In the 2023 BVL annual report, botanical food supplements were among the top five non-conformance categories

BVL surveillance portal: https://www.bvl.bund.de/EN/Tasks/04_Plant_protection_products/plant_protection_products_node.html

For any EGCG bulk supplier whose customers target the German market, providing a BfR-aligned labeling template — in German, with exact recommended phrasing — is not optional. It is the difference between a product that survives market surveillance and one that triggers a Schnellwarnung (rapid alert) through the EU RASFF system.

3.3 United Kingdom (Post-Brexit Divergence)

Since 31 December 2020, the UK operates an independent Novel Food regulatory framework administered by the Food Standards Agency (FSA). Green tea extract containing high-purity EGCG requires a Novel Food authorization under Regulation (EC) No 258/97 as retained in UK law (retained EU law, amended by SI 2019/702).

The UK's Novel Food public list includes approved green tea catechin entries, but the conditions of use (including maximum daily intake levels) are under active review by the FSA's Advisory Committee on Novel Foods and Processes (ACNFP). As of mid-2025, the FSA has not yet formally adopted the EU's 800 mg daily catechin ceiling but has signaled alignment in principle through its 2024 consultation paper.

FSA Novel Food guidance: https://www.food.gov.uk/business-guidance/regulated-products/novel-foods-guidance

Operational risk for suppliers: the UK represents a regulatory gray zone. Products authorized under the EU Novel Food regime before Brexit are grandfathered, but any modification to specification, source, or manufacturing process may trigger a new UK-specific authorization requirement. Suppliers who cannot document continuity of specification pre- and post-Brexit expose their UK customers to enforcement risk.

3.4 United States

Primary framework: Dietary Supplement Health and Education Act (DSHEA) of 1994, administered by FDA.

The central regulatory question for 98% EGCG in the US market is whether it qualifies as a New Dietary Ingredient (NDI) under Section 413(d) of the Federal Food, Drug, and Cosmetic Act.

FDA's NDI Guidance for Industry (2016, revised): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/new-dietary-ingredient-notifications-and-related-issues

The guidance establishes that a dietary ingredient not marketed in the US before October 15, 1994 requires an NDI notification with evidence of reasonable expectation of safety. Crude green tea extract has a clear pre-DSHEA history. However, a 98% single-compound isolate produced by chromatographic purification is chemically, analytically, and functionally distinct from a traditional hot-water or ethanol extract. FDA's own guidance states:

"A dietary ingredient may be considered 'new' if it has been chemically altered... including being extracted, concentrated, or otherwise processed beyond what is traditional." — FDA NDI Guidance, Section IV.A.3.

Whether 98% EGCG crosses this threshold has not been definitively settled by FDA enforcement. No NDI notification specifically for ≥ 95% EGCG isolate appears in the FDA's public NDI database. This ambiguity is itself a liability — the first Warning Letter or import alert targeting a high-purity EGCG product will retroactively define the compliance boundary for every supplier and brand in the market.

Additionally, 21 CFR Part 111 (cGMP for Dietary Supplements) requires that incoming raw materials be verified for identity, purity, strength, and composition. Sections 111.70(b) and 111.75(a)(1) mandate that manufacturers verify the identity of each incoming lot using at least one validated test method. For a 98% EGCG bulk supplier, this means providing documentation sufficient to support the buyer's incoming QC program — including HPLC chromatograms, reference standard lot numbers, system suitability data, and a method reference traceable to USP ⟨561⟩ or equivalent.

3.5 Australia

Regulatory authority: Therapeutic Goods Administration (TGA).

In Australia, green tea extract products containing concentrated catechins are increasingly subject to regulatory scrutiny under the Therapeutic Goods Act 1989 and the Australia New Zealand Food Standards Code. The TGA classifies certain high-dose green tea extract products as listed medicines (AUST L) rather than food, triggering GMP (PIC/S) and adverse event reporting requirements.

In November 2023, the TGA published an updated safety advisory on green tea extract products, requiring mandatory label warnings about potential liver injury for any listed medicine containing ≥ 500 mg/day green tea catechins. The TGA's Adverse Event Management System (AEMS) database contains multiple reports of hepatotoxicity associated with green tea catechin supplements in the Australian market.

TGA green tea safety advisory: https://www.tga.gov.au/safety/safety-advisories

For suppliers targeting Australian customers, the TGA's PIC/S GMP requirement means that the manufacturing facility must either hold PIC/S certification or provide documentation sufficient for the Australian sponsor to demonstrate GMP equivalence to the TGA.

3.6 Japan

Regulatory authority: Ministry of Health, Labour and Welfare (MHLW); Consumer Affairs Agency (CAA).

Japan regulates green tea catechin products under the Food Sanitation Act and the Foods with Function Claims (FFC) notification system (機能性表示食品). Under the FFC framework, EGCG-containing products can make specific health function claims (e.g., "contributes to reduction of body fat") if supported by a systematic review or clinical trial and notified to the CAA.

Japan has no equivalent to the EU's 800 mg daily catechin cap. However, the MHLW's 2024 review of functional food ingredient safety post-Kobayashi Pharmaceutical beni-kōji incident has introduced heightened scrutiny of all functional ingredients, including catechins, with particular attention to:

• Manufacturing process documentation (GMP compliance per MHLW ordinance)

• Stability data under Japanese Pharmacopoeia (JP) accelerated conditions (40°C/75% RH, 6 months)

• Heavy metal testing per JP General Tests ⟨2.23⟩ (Arsenic limit test) and ⟨2.56⟩ (Elemental impurities by ICP-MS)

3.7 Comparative Regulatory Matrix

4. Inorganic Arsenic Speciation: The Analytical Gap Between Your CoA and EU Enforcement

4.1 Why Total Arsenic Testing Is Necessary but Insufficient

Tea plants (Camellia sinensis) are documented arsenic accumulators. Arsenic speciation in tea leaves is dominated by organic forms (dimethylarsinic acid/DMA, arsenobetaine) with variable but non-trivial inorganic arsenic (iAs: arsenite As³⁺ + arsenate As⁵⁺) fractions depending on soil geochemistry, irrigation water source, and agricultural inputs.

EU Regulation 2023/915 (amending Regulation (EC) No 1881/2006) establishes maximum levels for inorganic arsenic — not total arsenic — in food. The regulation sets category-specific limits:

Full text: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32023R0915

While no specific iAs limit exists for "green tea extract" as a category in the current Annex, competent authorities in EU member states (particularly Germany's BVL) apply the general contaminant provisions and may use EFSA's established benchmark dose lower confidence limit (BMDL₀₁) of 0.3 µg/kg bw/day for inorganic arsenic as the risk assessment reference point.

4.2 Analytical Methods and Their Limitations

The critical point: a CoA reporting "Total Arsenic < 1.0 ppm" by ICP-MS tells the buyer nothing about the inorganic arsenic fraction. A sample with total As = 0.8 ppm could contain 0.6 ppm inorganic arsenic — a level that would trigger regulatory concern under EFSA's risk framework when combined with the concentrated dosing inherent to a 98% EGCG supplement product.

4.3 Blue Eye Biotech Co., Ltd. Standard

Every batch of 98% EGCG from Blue Eye Biotech Co., Ltd. is tested for inorganic arsenic by HPLC-ICP-MS (methodology aligned to EN 16802:2016), with a reporting LOQ of 0.02 ppm iAs. This is not available as a premium add-on. It is included in the standard CoA documentation package for every order, including 500g trial batches.

5. Residual Solvent Integrity: ICH Q3C(R8) Compliance and the Class 2 Solvent Question

5.1 Process Chemistry and Solvent Selection

Industrial purification of EGCG from crude green tea extract (40-60% catechins) to 98% single-compound purity involves sequential processing steps, each introducing specific solvents:

1. Liquid-liquid extraction (partitioning catechins from sugar/protein matrix): ethyl acetate, dichloromethane, or toluene

2. Column chromatography (catechin fractionation): methanol-water or acetonitrile-water mobile phases

3. Recrystallization (final purity uplift): ethyl acetate-heptane, ethanol-water, or acetone-water systems

4. Vacuum drying (solvent removal): determines residual solvent levels in final product

The relevant compliance framework is ICH Q3C(R8) — Impurities: Guideline for Residual Solvents (current version adopted by EMA, FDA, and PMDA). While ICH Q3C was developed for pharmaceutical products, it is increasingly adopted by reference in dietary supplement and food ingredient quality frameworks, including USP General Chapter ⟨467⟩ Residual Solvents.

5.2 The Risk That Silence Creates

The absence of a residual solvent panel on a CoA is not evidence that Class 2 solvents were absent from manufacturing. It is evidence that the supplier either did not test or chose not to disclose the results. In either case, the buyer inherits the liability.

Under 21 CFR 111.75(a)(1), US supplement manufacturers must verify the identity, purity, and composition of incoming components. If a raw material was manufactured using toluene or dichloromethane and no residual solvent test was performed, the manufacturer cannot certify compliance with cGMP.

Under USP ⟨467⟩, residual solvent testing uses GC-FID or GC-MS with headspace sampling. The chapter specifies Procedure A (water-soluble articles) and Procedure B (water-insoluble articles), with system suitability requirements including resolution and sensitivity validation.

Blue Eye Biotech Co., Ltd.'s position: exclusively Class 3 solvents (ethyl acetate, ethanol, water) in all stages of EGCG purification. Batch-level GC-FID residual solvent reports per USP ⟨467⟩ Procedure A included in standard documentation. Class 2 solvents tested and confirmed absent (< LOD) on every batch.

6. The Catechin Ratio Fingerprint: A 60-Second Authenticity Screen

A natural green tea extract — even one purified to 98% EGCG — retains trace quantities of co-occurring catechins: EGC, ECG, EC, and their galloylated and epimerized variants. The ratio of these minor catechins constitutes a fingerprint that reflects botanical origin and processing history.

Typical catechin ratio for legitimately purified 98% EGCG from C. sinensis var. sinensis:

Interpretive logic: a CoA that reports EGCG = 99.2% with all other catechins listed as "Not Detected" describes either (a) a synthetic EGCG isolate (commercially available but at ~5× the cost of botanical extract), (b) a spiked product (pure EGCG added to lower-purity base), or (c) an analytical artifact from a method that lacked the sensitivity or resolution to detect minor catechins. In all three cases, the buyer should request clarification.

Blue Eye Biotech Co., Ltd. reports all four major catechins (EGCG, EGC, ECG, EC) plus GCG and caffeine on every CoA, providing a complete fingerprint for incoming QC verification.

7. HPLC Chromatogram Literacy: What Every Buyer Must Be Able to Read

7.1 Reference Analytical Conditions

The following HPLC parameters represent a pharmacopeially aligned method for EGCG assay, consistent with USP ⟨561⟩ and EP 2799:

7.2 Expected Elution Order and Peak Identification

Under the conditions above, catechins elute in the following approximate order:

GC → EGC → Caffeine → EC → EGCG → GCG → ECG

The EGCG peak should appear between 18-24 minutes (method-dependent) as the dominant peak, with GCG eluting 1.5-3.0 minutes later. The resolution between EGCG and GCG peaks (Rs) must be ≥ 2.0 per EP 2799. If Rs < 1.5, the two peaks overlap and GCG is partially quantified as EGCG — artificially inflating the reported purity.

7.3 System Suitability: The Four Numbers That Validate the Entire Analysis

If these four numbers are not on the CoA or the accompanying chromatogram, the reported purity value is an unvalidated assertion.

8. The Total Cost of Ownership Model: Why Small-Batch Procurement Wins in 2026

Section 2 established that epimerization erodes EGCG purity over time. Section 3 established that regulatory requirements are tightening. The economic synthesis of these two facts is the Total Cost of Ownership (TCO) model, which evaluates the real cost of sourcing 100 kg of 98% EGCG annually under two competing procurement architectures.

Table: TCO Comparison — Bulk Annual vs. Agile Quarterly Procurement (100 kg/year, 98% EGCG)

Interpretation: Strategy A (traditional bulk annual) and Strategy B (quarterly agile) are near-identical in nominal TCO, but Strategy B delivers 1.1% higher average effective purity — meaning the buyer gets more potency per dollar spent. Strategy C (bi-monthly) has a higher nominal TCO due to freight and QC frequency, but delivers the lowest cost per kilogram of effective potency ($720/kg vs. $740/kg) and the narrowest regulatory risk window.

For companies whose finished product specifications leave ≤ 3% purity margin between raw material intake spec and end-of-shelf-life claim, Strategy B or C is not optional — it is the only architecture that avoids systematic out-of-spec risk.

Blue Eye Biotech Co., Ltd. is structurally built for Strategy B and C. 500g minimum order quantity. Quarterly price-lock available. Every lot ships with the full documentation package described in this report. No annual commitment. No volume penalty below 25 kg.

→ Start with a 500g evaluation batch: blueeyes-bio.com/contact

9. Supplier Audit Checklist: 12 Binary Questions to Evaluate Any 98% EGCG Vendor

This is not a scorecard. It is a pass/fail gate. A supplier failing four or more items represents uncontrolled risk in your supply chain.

10. Why Blue Eye Biotech Co., Ltd. Publishes This Data Against Its Own Short-Term Interest

Disclosing epimerization rates, GCG quantification, and regulatory gaps does not make selling EGCG easier. It makes selling low-quality EGCG harder.

That is the point.

Blue Eye Biotech Co., Ltd. operates on a thesis: that the EGCG bulk supplier market will bifurcate within 24 months into two tiers — those who can survive an informed buyer's audit, and those who cannot. This report is an accelerant for that bifurcation. Every procurement team that reads it and applies the audit checklist in Section 9 will eliminate at least one current vendor from consideration. We intend to be on the surviving side of that filter.

Our structural commitments:

• 98% EGCG, single-compound, anhydrous basis. GCG explicitly quantified. Four-catechin fingerprint standard.

• 500g minimum order. Nitrogen-flushed, pharmaceutical-grade aluminum pouch, desiccant-packed.

• Full analytical package per lot: HPLC chromatogram with system suitability, inorganic arsenic speciation (HPLC-ICP-MS), residual solvent GC-FID, moisture/ash, full microbiological panel (TPC, yeast/mold, E. coli, Salmonella, S. aureus, P. aeruginosa).

• Jurisdiction-specific compliance documentation: EU Reg 2022/2340 label templates, German BfR-aligned warning text, UK FSA pathway guidance, US NDI risk assessment framework, Australian TGA PIC/S documentation support.

• Certifications: GMP, ISO 9001:2015, Halal, Kosher.

We do not sell EGCG. We sell certainty.

→ Request batch documentation or a 500g trial order: blueeyes-bio.com/contact

References

1. Wang R, Zhou W, Jiang X. Reaction Kinetics of Degradation and Epimerization of Epigallocatechin Gallate (EGCG) in Aqueous System over a Wide Temperature Range. J Agric Food Chem. 2008;56(8):2694-2701. DOI: 10.1021/jf0730338

2. Sang S, Lee MJ, Hou Z, Ho CT, Yang CS. Stability of Tea Polyphenol (−)-Epigallocatechin-3-gallate and Formation of Dimers and Epimers under Common Experimental Conditions. J Agric Food Chem. 2005;53(24):9478-9484. DOI: 10.1021/jf0519055

3. Chen ZY, Zhu QY, Wong YF, Zhang Z, Chung HY. Stabilizing Effect of Ascorbic Acid on Green Tea Catechins. J Agric Food Chem. 2001;49(1):477-482. DOI: 10.1021/jf000970h

4. European Commission. Commission Regulation (EU) 2022/2340 of 30 November 2022. EUR-Lex

5. European Commission. Commission Regulation (EU) 2023/915 of 25 April 2023 (Contaminants in Food). EUR-Lex

6. U.S. FDA. New Dietary Ingredient Notifications and Related Issues — Guidance for Industry. FDA.gov

7. U.S. FDA. 21 CFR Part 111 — Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements.

8. EFSA Panel on Food Additives and Nutrient Sources (ANS). Scientific Opinion on the Safety of Green Tea Catechins. EFSA Journal. 2018;16(4):5239. EFSA

9. Bundesinstitut für Risikobewertung (BfR). Opinion No. 018/2018: Health Assessment of Food Supplements Containing Green Tea Catechins.

10. United States Pharmacopeia. General Chapters: ⟨561⟩ Articles of Botanical Origin; ⟨2232⟩ Elemental Contaminants in Dietary Supplements; ⟨467⟩ Residual Solvents.

11. European Pharmacopoeia. Monograph 2799: Green Tea Extract, Refined and Standardised.

12. ICH Harmonised Guideline Q3C(R8): Impurities — Guideline for Residual Solvents. Current Step 4, 2021.

13. ICH Harmonised Guideline Q1A(R2): Stability Testing of New Drug Substances and Products.

14. UK Food Standards Agency. Novel Foods Guidance. FSA.gov.uk

"This white paper is for industrial R&D and professional procurement purposes only. It is not intended for medical diagnostic or treatment advice."